STING1 and Sepsis: Targeting the mtDNA-STING pathway could potentially serve as a therapeutic approach to mitigate intestinal barrier disruption and promote mucosal healing in septic patients.STING pathway was activated in human sepsis and CLP-mouse model. Sting deficiency ameliorated multi-organs (lung, liver, and kidney) injury and intestinal inflammation, IEC apoptosis and intestinal barrier dysfunction, while STING agonist DMXAA following CLP procedure amplified disease pathogenesis in mice. Intraperitoneal injection DNase I inhibited intestinal damage and bacterial translocation.